New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
Nearly three in four patients said they would choose intravesical chemotherapy only as a last resort, rather than earlier in their treatment journey Over 80% believe immunotherapy has fewer side effects than chemotherapy, and 72% of immunotherapy recipients are satisfied with the duration of positive treatment effects* As bladder cancer rates continue to rise in the United States, ensuring access to innovative therapies that can improve long-term outcomes has become increasingly critical CULVER CITY, Calif., November 13, 2025 BUSINESS WIRE )--A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. ( NASDAQ: IBRX ) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical treatment conversations. Fewer than one in five patients surveyed (18%) report their healthcare providers (HCPs) discuss all available treatment options during most or every visit. More than four in five (84%) believe immunotherapy has fewer
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]Yahoo! Finance
- A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]Seeking Alpha
- A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences [Yahoo! Finance]Yahoo! Finance
- Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Analyst Actions
- 9/10/25 - HC Wainwright
IBRX
Sec Filings
- 11/10/25 - Form SCHEDULE
- 11/5/25 - Form 8-K
- 11/5/25 - Form 10-Q
- IBRX's page on the SEC website